Prothena (NASDAQ:PRTA - Free Report) had its price objective cut by Chardan Capital from $40.00 to $18.00 in a research report report published on Tuesday,Benzinga reports. They currently have a buy rating on the biotechnology company's stock. Chardan Capital also issued estimates for Prothena's FY2025 earnings at ($3.80) EPS and FY2026 earnings at ($3.55) EPS.
Several other research firms have also recently weighed in on PRTA. Oppenheimer increased their price objective on Prothena from $58.00 to $62.00 and gave the stock an "outperform" rating in a research report on Friday, February 7th. Cantor Fitzgerald raised shares of Prothena to a "strong-buy" rating in a research report on Tuesday, May 13th. HC Wainwright cut their price objective on shares of Prothena from $48.00 to $30.00 and set a "buy" rating for the company in a report on Friday, May 9th. Piper Sandler raised their target price on shares of Prothena from $94.00 to $110.00 and gave the stock an "overweight" rating in a report on Wednesday, February 26th. Finally, JMP Securities cut their price target on Prothena from $80.00 to $78.00 and set a "market outperform" rating for the company in a research note on Friday, May 9th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and four have given a buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $31.50.
Read Our Latest Analysis on PRTA
Prothena Price Performance
Prothena stock traded down $0.11 during mid-day trading on Tuesday, hitting $4.59. 1,963,387 shares of the company's stock traded hands, compared to its average volume of 686,990. The firm has a 50 day simple moving average of $8.88 and a two-hundred day simple moving average of $12.48. Prothena has a fifty-two week low of $4.32 and a fifty-two week high of $25.42. The stock has a market cap of $247.07 million, a price-to-earnings ratio of -2.00 and a beta of 0.11.
Prothena (NASDAQ:PRTA - Get Free Report) last announced its earnings results on Thursday, May 8th. The biotechnology company reported ($1.12) EPS for the quarter, missing the consensus estimate of ($0.92) by ($0.20). The company had revenue of $2.83 million for the quarter, compared to the consensus estimate of $8.18 million. Prothena had a negative return on equity of 22.67% and a negative net margin of 90.50%. The business's quarterly revenue was up 5500.0% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.34) EPS. On average, research analysts anticipate that Prothena will post -4.04 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the company. Wellington Management Group LLP lifted its stake in Prothena by 1.3% during the first quarter. Wellington Management Group LLP now owns 5,199,528 shares of the biotechnology company's stock worth $64,344,000 after purchasing an additional 68,652 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Prothena by 11.5% during the 4th quarter. Vanguard Group Inc. now owns 1,403,838 shares of the biotechnology company's stock worth $19,443,000 after buying an additional 144,737 shares during the last quarter. Siren L.L.C. lifted its position in shares of Prothena by 16.7% during the 1st quarter. Siren L.L.C. now owns 1,283,555 shares of the biotechnology company's stock worth $15,884,000 after buying an additional 183,715 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in Prothena by 1.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 864,833 shares of the biotechnology company's stock valued at $11,980,000 after buying an additional 10,783 shares in the last quarter. Finally, Federated Hermes Inc. raised its stake in Prothena by 84.3% during the fourth quarter. Federated Hermes Inc. now owns 746,177 shares of the biotechnology company's stock worth $10,335,000 after acquiring an additional 341,274 shares in the last quarter. 97.08% of the stock is owned by institutional investors.
Prothena Company Profile
(
Get Free Report)
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.
Featured Stories
Before you consider Prothena, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prothena wasn't on the list.
While Prothena currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
